$2.56
+0.01(0.20%)
Mkt Cap $96M
$2.08
$8.24
52-Week Range
At a Glance
AI-generatedGenelux Corporation (GNLX), a clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies, reported a net loss of $32.1 million for FY 2025, up 7.6% YoY from $29.9 million in FY 2024, driven by higher operating expenses of $33.2 million versus $31.7 million prior year.
8-K
Genelux Corporation entered into a Sales Agreement with TD Securities (USA) LLC on March 19, 2026, enabling the offer and sale of up to $100,000,000 of its common stock through at-the-market offerings. Net proceeds will fund general corporate purposes, including research and development, clinical trials, capital expenditures, and working capital.$96M
Market Cap
$8.1K
Revenue
-$33M
Net Income
Employees24
Fundamentals
How The Business Makes Money
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001231457
ISINUS36870H1032
Phone858 483 0024
Address2625 Townsgate Road, Westlake Village, CA, 91361, US
SEC EDGAR